PRESS RELEASE
News
-
-
PRESS RELEASE
Silver Spruce Appoints Paul K. Smith and William Fleming to Company’s Advisory Board
Silver Spruce Resources Inc. appoints Paul K. Smith and William Fleming to Advisory Board. Smith brings mineral deposits expertise, Fleming offers strategic foresight and corporate governance. Company explores new projects in Canada, Mexico, and the USA -
PRESS RELEASE
ARway.ai Announces Substantial Increase in Revenue Growth Following Map D Acquisition
ARway reports robust +194% increase in unaudited revenue and 5% gross margin growth post Map Dynamics acquisition. Nextech3D.AI renews share purchase warrant program to reward workforce and align interests with company's success -
PRESS RELEASE
Gungnir Receives Swedish Gold Line Permit Approvals and Announces Collaboration with LTU for Ni-Cu-PGE Study
Gungnir Resources Inc. obtains final approval for permit applications within Knaften-Hemberget gold project in Sweden. Collaboration with LTU for high-grade nickel deposit study -
PRESS RELEASE
EV Nickel Drills Best Hole to Date & Expands Nickel Sulphide Zone at Gemini North Intersecting 186.5m Grading 0.36% Nickel
EV Nickel Inc. announces successful results from diamond drill program at the Gemini North Zone on Shaw Dome Project. The program reveals high-grade nickel mineralization, enrichened sulphur contents, and potential for a magmatic sulphide source -
PRESS RELEASE
UniDoc Announces Purchase Agreement for AGNES Connect Software from AMD Telemedicine
UniDoc Health Corp. announces strategic acquisition of AGNES Connect software from AMD Telemedicine, enhancing eHealth capabilities. Acquisition to accelerate software platform expansion, strengthen telehealth offering, and increase shareholder value -
-
-
PRESS RELEASE
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Xenetic Biosciences reports encouraging preclinical data on DNase-based technology targeting NETosis for difficult cancers. Focus on clinical studies partnerships and DNase I development program for pancreatic carcinoma -
PRESS RELEASE
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
Telomir-1 by Telomir Pharmaceuticals demonstrates tumor growth inhibition by 50% in prostate cancer model, suppresses cancer progression, and neutralizes chemotherapy toxicity, providing breakthrough findings
